https://www.bioworld.com/rss en-us Med-tech M&As through the first half (H1) of 2026 reached $75.73 billion in collective value, the highest H1 total since 2022’s $120.4 billion and well above every other year in BioWorld’s records. June contributed $12.21 billion, a rebound from May’s relatively quiet $1.51 billion. BioWorld’s records. June contributed $12.21 billion, a rebound from May’s relatively quiet $1.51 billion. ]]> http://www.bioworld.com/articles/732530 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732530-danaher-masimo-close-caps-med-techs-strongest-first-half-since-2022 M&A letters over missing puzzle pieces For decades, treatment options for osteoarthritis have followed a familiar path: As cartilage deteriorates and pain worsens, conservative therapies eventually give way to joint replacement surgery. Australian regenerative medicine company Integrant Pty Ltd. wants to change that trajectory. Rather than replacing damaged joints, the Sydney-based company is building a platform designed to regenerate cartilage and preserve joint function by combining biologics, medical devices and artificial intelligence. http://www.bioworld.com/articles/732517 Thu, 09 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732517-integrant-targets-cartilage-repair-with-ai-biologics-platform Illustration of leg anatomy with target around knee Of all the U.S. SEC’s recent proposed rules to make going, and staying, public more attractive, perhaps the most beneficial for biopharma and med-tech startups is the amendment that would give public companies the flexibility to file semi-annual rather than quarterly reports, Ben Bradford, head of external affairs at Massbio, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/732433 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732433-sec-reform-good-for-life-sciences-startups-but-getting-pushback Gears with regulatory words After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? With developments accelerating in the field, BioWorld's special series explores the advancements in the space, looking at the implanted technologies, their potential to transfer care, what’s driving investor interest and the challenges ahead. BioWorld's special series explores the advancements in the space, looking at the implanted technologies, their potential to transfer care, what’s driving investor interest and the challenges ahead.]]> http://www.bioworld.com/articles/732478 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732478-science-fiction-realized-bci-tech-is-here Blue brain with computer chip Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. http://www.bioworld.com/articles/732474 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732474-bellaseno-speeds-breast-scaffold-trial-as-j-and-j-deal-clears-path-to-market Illustration of Bellaseno's scaffold placed in the breast Bellaseno’s regenerative absorbable breast scaffold. Credit: Bellaseno. Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732472 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732472-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device, which can reduce their symptoms in as little as four weeks. The treatment, designed for at-home use of 30-minute daily sessions, was approved for use within the Department of Veterans Affairs after the company secured FDA de novo approval. http://www.bioworld.com/articles/732270 Mon, 06 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732270-neurovalens-brings-fda-cleared-ptsd-therapy-to-us-veterans Modius Spero wearable neuromodulation device Neurovalens Ltd.’s Modius Spero wearable neuromodulation device. Credit: Neurovalens. BioWorld's offices were closed in observance of Independence Day in the U.S. No issue was published Friday, July 3. BioWorld's offices were closed in observance of Independence Day in the U.S. No issue was published Friday, July 3.]]> http://www.bioworld.com/articles/732296 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732296-holiday-notice Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. http://www.bioworld.com/articles/732275 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732275-bellaseno-speeds-breast-scaffold-trial-as-j-and-j-deal-clears-path-to-market Illustration of Bellaseno's scaffold placed in the breast Bellaseno’s regenerative absorbable breast scaffold. Credit: Bellaseno. Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732271 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732271-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion. The figure reflects a sector that is holding well above the low years of 2022 and 2023. http://www.bioworld.com/articles/732392 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732392-follow-ons-lead-a-mixed-first-half-of-2026-for-med-tech-financing Global currency Regardless of whether the Republicans or Democrats come out on top in November’s midterm congressional elections, some of the state primaries in the U.S. have already guaranteed major shuffles in key House and Senate committees overseeing national health issues. http://www.bioworld.com/articles/732262 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732262-us-primaries-continue-to-rattle-congressional-health-leadership U.S. Capitol building Zimmer Biomet Holdings Inc.’s deal to buy Pacira Biosciences Inc.’s Iovera system for up to $140 million and Eurobio Scientific SA’s acquisition of Caredx Inc.’s lab products business for $171.2 million are symptomatic of a broader trend among med-tech and diagnostics companies using targeted acquisitions to strengthen specific areas of their portfolio. http://www.bioworld.com/articles/732261 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732261-cool-move-by-zimmer-part-of-med-techs-tuck-in-deals-trend Handshake icon engraved on metal hexagonal background Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill patients have received an implant to treat Parkinson’s disease, which is DBS’ greatest success story. http://www.bioworld.com/articles/732241 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732241-deep-brain-stimulation-from-the-shallows-tomorrows-bci-technology Black wavy lines forming an abstract sound wave.png Roche Holding AG is looking to take a share of Illumina Inc.’s dominance in the gene sequencing market with the launch of Axelios 1, its next-generation sequencing (NGS) platform designed for accuracy, speed, flexibility, scalability and cost efficiency. The move signals a potential shift in the sequencing landscape as the technology aims to address critical bottlenecks in genomics. http://www.bioworld.com/articles/732228 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732228-roche-launches-axelios-1-sequencing-platform-to-rival-illumina DNA NGS genome sequencing Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model moves closer to adoption in real-world clinical and military practice, technological advances are sparking concerns over public health, ethics and national security. http://www.bioworld.com/articles/732225 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732225-ascending-bci-systems-deepen-national-security-ethical-concerns Brain made of chip and circuits Johnson & Johnson this week launched its dual-energy Thermocool Smarttouch SF platform in Europe bringing another option to physicians looking to enhance their electrophysiology procedures. The system combines radiofrequency (RF) and pulsed field ablation in one device to treat atrial fibrillation, entering what is becoming an increasingly crowded market for cardiac ablation technology. http://www.bioworld.com/articles/732175 Fri, 26 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732175-j-and-j-brings-dual-energy-cardiac-ablation-technology-to-europe Johnson & Johnson’s Thermocool Smarttouch SF platform J&J’s Thermocool Smarttouch SF platform. Credit: Johnson & Johnson An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue. Investors are betting that a deeper understanding of the brain will allow BCI systems to address the significant unmet need affecting millions of people with neurological disorders. They are also chasing an opportunity where the market for BCIs could reach $400 billion – in the U.S. alone. http://www.bioworld.com/articles/732170 Fri, 26 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732170-investors-bet-on-transformative-bci-tech-for-neuro-disorders Digital brain with dollar sign Adhesives innovator H.B. Fuller Co. is offering £2.85 per share in cash to buy Advanced Medical Solutions Group plc, expanding its technologies, commercial footprint and manufacturing capabilities across the globe. http://www.bioworld.com/articles/732163 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732163-advanced-medical-solutions-takeout-offer-worth-659m Acquisition target Merck KGaA has agreed to buy Bio-Techne Corp. for an enterprise value of approximately $11.3 billion, in a bid to strengthen its life sciences business. The company is offering $73 per share in cash, a 36% premium to Bio-Techne's one-month volume-weighted average trading price, and a 24% premium to the company’s previous close on June 24. The deal will expand Merck’s position in multi-omics, spatial biology, cell and gene therapy, precision diagnostics and advanced research tools. http://www.bioworld.com/articles/732157 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732157-merck-to-buy-bio-techne-for-113b-to-boost-life-sciences-portfolio Lab glassware and scientist With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the latest installment of BioWorld’s series on the BCI field, Rotem Kopel, CEO of Ability Neurotech SA, explains that following in the footsteps of the established players has its advantages. “It's not too bad to be a fast follower to a company like Neuralink.” Ability and its peers are either building more complete systems, or exploring different approaches from electrodes with newer materials to nanoparticles, while addressing technical and clinical challenges identified by earlier entrants and targeting different indications. BioWorld’s series on the BCI field, Rotem Kopel, CEO of Ability Neurotech SA, explains that following in the footsteps of the established players has its advantages. “It's not too bad to be a fast follower to a company like Neuralink.” Ability and its peers are either building more complete systems, or exploring different approaches from electrodes with newer materials to nanoparticles, while addressing technical and clinical challenges identified by earlier entrants and targeting different indications.]]> http://www.bioworld.com/articles/732156 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732156-next-wave-of-bci-firms-builds-on-pioneers-to-tackle-challenges Subsense BCI platform Subsense's non-invasive BCI platform uses nanoparticles and a wearable headset. Credit: Subsense Inc. Tissium SA secured €60 million (US$68 million) in a financing package, which includes €30 million in a series D2 round and a €30 million facility from the European Investment Bank. The funds will be used to support the company's commercial and clinical activities, as well as its pipeline development and expansion of its platform technology, which removes the need for sutures and leads to better nerve repair. http://www.bioworld.com/articles/732080 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732080-tissium-secures-60m-to-advance-sutureless-tissue-repair-platform Tissium polymer technology Tissium's polymer technology. Credit: Tissium SA The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced players, with fully developed BCI systems, the sector is approaching an inflection point as the technology transitions from early feasibility studies into pivotal trials. The focus now for many is on generating the long-term safety, efficacy and real-world usability data needed to support regulatory approval and broader clinical adoption. http://www.bioworld.com/articles/732074 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732074-brain-computer-interfaces-are-here-but-long-road-ahead Cortec Brain Interchange BCI system Cortec’s Brain Interchange system is a fully implantable, wireless, bidirectional closed-loop platform that records neural activity and delivers stimulation through soft subdural electrocorticography electrodes, without penetrating brain tissue. Credit: Cortec GmbH Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at how simultaneous breakthroughs in AI technology are pushing the BCI field from a theoretical concept to a potential real-world, clinical option for individuals, particularly in China where the National Medical Products Administration greenlighted the world’s first invasive BCI system – Neuracle Medical Technology Co. Ltd.’s Neural Electronic Opportunity – for clinical use in March 2026. BioWorld’s series on the Brain-Computer Interface (BCI) field looks at how simultaneous breakthroughs in AI technology are pushing the BCI field from a theoretical concept to a potential real-world, clinical option for individuals, particularly in China where the National Medical Products Administration greenlighted the world’s first invasive BCI system – Neuracle Medical Technology Co. Ltd.’s Neural Electronic Opportunity – for clinical use in March 2026.]]> http://www.bioworld.com/articles/732062 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732062-2026-marks-critical-turning-point-for-bci-technology Patient using Neuracle NEO system A patient grasps a bottle with a prosthetic hand using Neuracle’s NEO system, codeveloped by Tsinghua University School of Medicine. Credit: Tsinghua University Croívalve Ltd. secured a further $20 million in series B financing for its Duo Adapt system, a transcatheter device that treats tricuspid regurgitation. The company also received $7 million from the European Innovation Council and the Disruptive Technologies Innovation Fund in grant financing. Croívalve will use the funds to expand its clinical study, which is evaluating the safety and performance of the Duo Adapt system in patients with severe or greater symptomatic tricuspid regurgitation. http://www.bioworld.com/articles/732061 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732061-croivalve-secures-27m-for-duo-adapt-tricuspid-device Croívalve Duo System The Duo system is a novel transcatheter heart valve designed to preserve the patient’s native anatomy while treating tricuspid regurgitation. Credit: Croívalve Ltd. Matricelf Ltd. has initiated a pivotal IND-enabling efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. http://www.bioworld.com/articles/732115 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732115-matricelf-studies-neural-tissue-implant-for-spinal-cord-injury 3D illustration of transparent human torso with close up of spinal cord More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural signals are increasingly moving from labs to real-world settings to test their potential to treat neurological disorders. At the same time, startups are emerging, investors are pouring money into the space and companies are accelerating their development programs. After decades of clinical research and false starts, are BCI systems finally here? http://www.bioworld.com/articles/732045 Mon, 22 Jun 2026 11:00:00 -0400 https://www.bioworld.com/articles/732045-have-brain-computer-interfaces-finally-arrived Blue brain with computer chip Med-tech M&A value through the first five months of 2026 reached $62.98 billion, the highest total for the period since 2022’s $84.13 billion and a dramatic step up from 2025’s $22.4 billion and 2024’s $21.86 billion over the same stretch. http://www.bioworld.com/articles/731922 Thu, 18 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731922-boston-sci-mirus-pact-lifts-med-tech-dealmaking-to-record-45b-in-may Boston Scientific signage Credit: Boston Scientific Corp. For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges are well known, such as loss of muscle mass loss, compliance and accessibility. With more treatments moving through the pipeline, innovation and technology will be key to supporting long-term use, delegates heard at the HLTH Europe conference in Amsterdam on June 17. http://www.bioworld.com/articles/731908 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731908-glp-1s-need-technologies-for-long-term-use Wireframe of feet and scale Liability remains one of the biggest barriers to the adoption of AI in healthcare. As more tools get developed for use in clinical settings, a key question persists: Who is ultimately at fault when something goes wrong – the hospital, the clinician or the developer? That uncertainty is making clinicians hesitant to adopt new technologies, delegates heard at the HLTH Europe conference in Amsterdam on June 16. http://www.bioworld.com/articles/731892 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731892-hlth-europe-panel-on-ai-liability-in-healthcare-who-is-responsible Doctor, tablet and medical holograms